Antimicrobial resistance in five countries including USA, India, China, UK, and Pakistan. The analysis reveals high and very high levels of AMR in these countries, with respiratory, urinary tract, bloodstream, and surgical site infections being the most common. The identified resistant pathogens include E. coli, K. pneumonia, P. aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. Carbapenems, fluoroquinolones, and cephalosporins are commonly used antibiotics, but resistance mechanisms such as enzyme production and altered target sites contribute to the problem. The estimated annual costs associated with AMR are substantial, with the USA spending $35 billion, India $2.5 billion, China $12 billion, UK £1.2 billion, and Pakistan PKR 361.9 million. Various reporting agencies, including the CDC, WHO, and national health organizations, monitor and report on AMR. The abstract also highlights resistance mechanisms such as extended-spectrum beta-lactamase (ESBL), methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistance (MDR), and carbapenem-resistant Enterobacteriaceae (CRE), along with their respective costs. Our findings underscore the urgent need for global collaboration to address AMR effectively. Strategies must be improved surveillance systems, liable antibiotic use, and the development of new antimicrobial agents are decisive to combat the growing threat of AMR and preserve the effectiveness of existing antibiotics.

When microorganisms like bacteria, viruses, fungi, and parasites develop resistance to antimicrobial agents, this is known as antimicrobial resistance (AMR). (Marston, Dixon, Knisely, Palmore, & Fauci, 2016). Some of these include improper or excessive antibiotic usage, inadequate infection management, and dirty conditions of residence (Acar & Rostel, 2001). Because AMR makes it more difficult to treat infections, it is becoming a major public health issue that is driving up healthcare costs and threatening patient safety. (Hofer, 2019).

The goal of this study was to find better ways to prevent and control infections, encourage the responsible use of antimicrobials, identify and test novel antimicrobial agents, and better track and report patterns of resistance.

To Understand the Impact of AMR on Public Health

Most at risk are elder people, young children, and individuals with compromised immune systems, all of whom can be adversely affected by antimicrobial resistance pathogens and suffer more morbidity and death as a result (Okeke et al., 2005). Multidrug-resistant bacterial infections, such as those caused by MRSA, can be more challenging to treat, requiring longer hospital stays, more intense care, and potentially more expensive therapies, as discussed by Holmes et al. This may place an undue strain on the healthcare system and lead to higher healthcare costs. Healthcare expenditures and mortality rates aren't the only things affected by antimicrobial resistance. The social and economic repercussions may be far-reaching. Reduced production due to increased morbidity and the loss of a productive workforce due to disease and death are two examples. Antimicrobial resistance (AMR) has repercussions outside the medical and scientific communities; for example, the overuse of antibiotics in cattle production has been linked to the emergence of AMR (Mehdi et al., 2023), (Holmes et al., 2016).

Overuse and misuse of antibiotics, inadequate infection prevention and control methods, a dearth of novel antibiotics, international trade and travel, antibiotic use in agriculture, and subpar sanitation and hygiene all contribute to the alarming rise in antimicrobial resistance (AMR). These conditions promote the growth and dissemination of antibiotic-resistant bacteria, which in turn makes it more difficult to contain and treat infectious diseases. To restrict the spread of AMR and protect the efficacy of antibiotics, strong measures of prevention and control are required (Laxminarayan et al., 2013).

Antimicrobial medications, such as antibiotics, can be overused and misused, which can lead to resistance in human and animal populations. Frequent use of antimicrobials can foster the development of bacteria that is resistant to the drugs. In recent years, progress in creating new antimicrobial medications has halted. This reduces the number of potential treatments for infections caused by antibiotic-resistant bacteria. The rapid and widespread growth of resistant germs across the world is facilitated by international travel and trade. Poor hand hygiene and other inadequate infection control procedures can facilitate the spread of antibiotic-resistant bacteria in healthcare facilities. When people don't have access to clean water and sanitation, infectious diseases proliferate and more people need to take antimicrobials, which can lead to resistance. The raising of animals with the aid of antimicrobial medications can promote the evolution of drug-resistant microorganisms. Reducing the spread of AMR and protecting the use of antimicrobial medicines both require attention to these variables. This calls for a concerted effort on the part of healthcare professionals, government officials, and the general public (Laxminarayan et al., 2013).

Mechanism of Resistance Developed by Extended-spectrum Beta-lactamase

Bacteria that create extended-spectrum beta-lactamase (ESBL) enzymes are resistant to multiple classes of beta-lactam antibiotics. (Coque, Baquero, & Cantón, 2008). Melzer and colleagues studied the Penicillin-binding proteins (PBPs) were the enzymes involved in bacterial cell wall construction, and beta-lactam antibiotics function by binding to and blocking the activity of these enzymes. As a result, bacterial cell wall production was disrupted, and the bacteria decrease. The beta-lactam ring in these antibiotics was hydrolyzed by enzymes produced by ESBL-producing bacteria leaving them ineffective. Beta-lactamases of which ESBLs were also a subset and categorized according to their substrate selectivity and mechanisms of resistance. Unlike other beta-lactamases like penicillinases and cephalosporinases, extended-spectrum beta-lactamases (ESBLs) are capable of hydrolyzing a wider variety of beta-lactam antibiotics (Melzer & Petersen, 2007).

The acquisition of plasmids which are mobile replicating genetic components that may be transmitted between bacteria is commonly linked to the evolution of ESBL-mediated resistance. Bacteria that make ESBLs have acquired the ability to produce these enzymes and acquire resistance to beta-lactam antibiotics by acquiring plasmids encoding the genes that code for ESBLs. Alterations to the bacterial cell wall or the presence of efflux pumps, both of which can remove antibiotics from the bacterial cell, are two additional resistance mechanisms that may be present in ESBL-producing bacteria (Khanfar, Bindayna, Senok, & Botta, 2009; Zeb et al., 2022). Infections produced by ESBL-producing bacteria can be particularly challenging to treat because of these resistance mechanisms. ESBL-mediated resistance poses a significant threat to public health because it reduces the efficacy of antibiotics and raises the risk of life-threatening infections. Antimicrobial stewardship programs, infection prevention and control measures, and the prudent use of antibiotics are all examples of prevention tactics that can help lower the number of ESBL-producing bacteria and other multidrug-resistant germs in a given environment (Andes, Craig, & Infection, 2005), (Ahmed et al., 2022).

Mechanism of Resistance Developed by Methicillin-resistant Staphylococcus Aureus

Methicillin (a beta-lactam antibiotic) is still effective against MRSA, the bacteria have developed resistance to a number of other medications. Methicillin-resistant Staphylococcus aureus is dependent on a movable genetic element that is referred to as the staphylococcal cassette chromosome mec (SCCmec). A penicillin-binding protein (PBP2a) with a lower affinity for beta-lactam medicines is encoded by the mecA gene in SCCmec. PBP2a is unaffected by the presence of beta-lactamase-producing microbes, hence MRSA can continue to resist these antibiotics. (Stefani et al., 2012). In addition to the mecA gene, which renders many antibiotics ineffective against MRSA infections, SCCmec has other genes that confer resistance to a wide range of antibiotics, including aminoglycosides and macrolides. In addition to modifying its PBPs, MRSA could develop resistance by producing efflux pumps, which can expel drugs from the bacterial cell, or by altering the bacterial cell wall. Transduction, conjugation, and transformation are all examples of horizontal gene transfer that S. aureus can adopt to acquire and spread SCCmec. This has the potential to hasten the spread of MRSA in both clinical and community settings (Algammal et al., 2020).

Multi-drug Resistance (MDR) patterns used by Bacteria

Multidrug-resistant (MDR) bacteria are those that are resistant to multiple classes of antibiotics, which makes them difficult to treat and often results in longer hospital stays, higher healthcare costs, and increased mortality rates (Jubair et al., 2021). Multidrug-resistant (MDR) bacteria's mechanisms of resistance vary per organism and antibiotic, but numerous overarching pathways contribute to MDR overall: Antibiotics are rendered useless by many bacteria due to their efflux pumps, which actively pump antibiotics out of the bacterial cell. It's possible that multidrug-resistant bacteria over-express these pumps, giving them an advantage in clearing the body of medications. Antibiotic resistance is often the result of alterations made by bacteria to the target site of the antibiotic, such as PBPs or ribosomes, which prevents the antibiotic from binding properly. This can be accomplished through horizontal gene transfer or through mutations in the bacterial DNA. Some bacteria develop enzymes, such as beta-lactamases, that can deactivate antibiotics, making them useless. Multidrug-resistant bacteria (MDR bacteria) may develop several distinct enzymes, each of which can neutralize a different group of antibiotics. Bacteria can become resistant to antibiotics by modifying their cell membranes or cell walls to make them impermeable to the drugs. The permeability of the bacterial cell can be changed through mutations or the acquisition of new genes. Multiple drug resistance bacteria (MDR) are resistant to many different antibiotics because they exploit a combination of resistance mechanisms. The selective pressure for the formation and spread of resistant types of bacteria is typically linked to the overuse and misuse of antibiotics. The development of novel medicines and alternative treatment options, together with proper antibiotic use, infection prevention and control measures, and other measures, are all necessary to stop the rise of multidrug-resistant bacteria (Otsuka & Bulletin, 2020), (Yuan et al., 2021), (Boyanova, Markovska, & Mitov, 2019).

Mechanism of resistance developed by Carbapenem-resistant Enterobacteriaceae

Carbapenem-resistant Gram-negative bacteria belonging to the family Enterobacteriaceae have become resistant to carbapenem medicines, which are typically reserved for the treatment of life-threatening diseases (Tilahun, Kassa, Gedefie, Ashagire, & Resistance, 2021). CRE has developed several resistance mechanisms, including Carbapenemases are enzymes that may degrade the carbapenem antibiotics, rendering them useless. These enzymes are frequently found on plasmids, which are movable genetic elements and can help the spread of CRE by allowing them to move easily between bacteria (Suay-García & Pérez-Gracia, 2019). To prevent carbapenem drugs from penetrating the bacterial cell wall and reaching their target site, certain CRE may have undergone modifications to their outer membrane, rendering them impermeable. Similar to multidrug-resistant bacteria, carbapenem medicines may not be as effective against some CRE because they overexpress efflux pumps that actively remove the drugs from the bacterial cell. Some carbapenem-resistant enterobacteria (CRE) may acquire mutations in the target sites of carbapenem antibiotics, such as PBPs or porins that render the antibiotics ineffective. Similar to multidrug-resistant bacteria, CRE may be resistant to various antibiotic classes due to a combination of resistance mechanisms. Overuse and improper use of antibiotics, especially carbapenems, can result in the selection and dissemination of resistant bacteria, which can contribute to the development of CRE. The spread of CRE can be stopped through a combination of infection prevention and control strategies, responsible use of antibiotics, and the discovery of novel drugs (Han et al., 2020), (Ding et al., 2019).

The human health consequences of antimicrobial resistance (AMR) are substantial, including higher rates of sickness, mortality, and healthcare expenditures (Dunachie, Day, & Dolecek, 2020). Among the many negative effects of AMR on human health is an increasing disease burden. Longer hospital stays, more serious illnesses, and increased morbidity and mortality rates have all been linked to infections caused by AMR bacteria. Methicillin-resistant Staphylococcus aureus (MRSA) infections have a higher mortality rate than other types of bacterial infections. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) have been linked to higher fatality rates and longer hospital stays. AMR illnesses have a higher mortality rate than those caused by infections caused by bacteria that aren't resistant. Up to 50% of mortality has been linked to infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Due to the increased difficulty and expense of treating AMR infections, healthcare expenditures have increased. The cost of treating an infection caused by MRSA can be up to three times that of treating an infection caused by a non-resistant variant of the bacteria. As with non-resistant bacteria, the cost of treating a patient infected with a CRE strain can be up to three times greater. The consequences of AMR on human health are substantial and varied. It's a big issue for public health and calls for cooperation from government, medical professionals, and citizens. Appropriate antibiotic usage, infection prevention and control measures, and funding for antibiotic research and development are all examples of tactics that can be used to slow or stop the spread of AMR (MacKinnon et al., 2020; Dadgostar & Resistance, 2019; Limmathurotsakul et al., 2019).

Evaluate the Economic Costs of AMR, Costs of Treatment, Lost Productivity, and Increased Healthcare Expenditures

Antimicrobial resistance (AMR) not only has significant impacts on human health but also has economic costs associated with it (Zhen et al., 2021). There are some ways in which AMR affects the economy such as increased healthcare costs: AMR infections require more complex and expensive treatments, including longer hospital stays and the use of more expensive antibiotics. These increased healthcare costs can place a burden on individuals, healthcare systems, and governments. A study by the World Bank estimated that by 2050, the cumulative economic costs of AMR could reach $100 trillion globally. Lost productivity: AMR infections can result in longer hospital stays, extended sick leave, and even death, all of which can lead to lost productivity. This can have a significant impact on individuals, businesses, and the economy as a whole (Okunogbe et al., 2022). Impact on agriculture and food production: AMR in animals and crops can also have economic costs. For example, the use of antibiotics in agriculture can contribute to the development of AMR, which can reduce crop yields, increase animal mortality, and result in economic losses for farmers. Impact on international trade: AMR can also have an impact on international trade, as countries may impose restrictions on the import of goods from countries with high levels of AMR. This can have economic implications for countries that rely on international trade for economic growth. The economic costs of AMR are significant and can have wide-ranging impacts on individuals, healthcare systems, businesses, and the economy as a whole. Governments, healthcare providers, and other stakeholders ought to work together to address AMR by funding antibiotic research and development, bolstering infection prevention and control efforts, and encouraging more responsible antibiotic use (Paramasivam et al., 2023), (Wozniak, Barnsbee, Lee, Pacella, & Control, 2019; ).

Antimicrobial resistance (AMR) is a complex problem that requires a multifaceted approach to address it effectively (Harun et al., 2022). Effective current approaches to antimicrobial resistance include: To slow the spread of antibiotic-resistant bacteria, many institutions have implemented antimicrobial stewardship programs (ASPs). Guidelines and protocols for antibiotic usage, monitoring and tracking antibiotic use and resistance, and teaching and training for healthcare personnel are typical components of such programs. There is evidence that ASPs can help curb the overuse of antibiotics, boost patient outcomes, and slow the spread of antimicrobial resistance. The primary goal of infection prevention and control strategies is to stop the spread of disease, including illnesses caused by bacteria resistant to antibiotics. Hygiene practices such as washing one's hands, disinfecting one's surroundings, wearing protective gear, and avoiding contact with others are all part of these protocols. Infection prevention and control techniques have been demonstrated to be useful in lowering the spread of bacteria resistant to antibiotics in healthcare facilities. New antibiotic development is necessary to combat the spread of antimicrobial resistance. However, there are many obstacles to developing new antibiotics, such as the high failure rate of antibiotic research programs and the lengthy and expensive nature of the process itself. While these approaches have shown promise in combating AMR, they are not without their share of difficulties in terms of both execution and long-term viability. For instance, healthcare providers may avoid adopting ASPs despite their potential benefits. Measures to prevent and control infections in healthcare facilities can be costly and difficult to adopt routinely. Many factors, including legislative constraints and financial incentives from the pharmaceutical sector, work against the development of new antibiotics. To effectively combat AMR, a collaborative effort by healthcare providers, governments, and other stakeholders is required. Antimicrobial stewardship programs and education and awareness campaigns are necessary, as are investments in the development of new antibiotics, the implementation of effective infection prevention and control measures, and the promotion of responsible antibiotic usage (Iwu & Patrick, 2021), (Villanueva et al., 2022), (Lacotte, Årdal, Ploy, & Control, 2020).

The development of resistance to antibiotics is a major public health problem that threatens international health safety. Antibiotic-resistant bacteria are a major threat because they can increase healthcare expenditures, lengthen the length of time patients spend in the hospital, and even cause death. The financial toll of AMR is high, and it's only going to climb in the years to come. To combat the spreading issue of AMR, the discovery of novel antibiotics is essential. New antibiotic development, however, is time-consuming, expensive, and fraught with difficulty. Incentives for pharmaceutical businesses, removal of regulatory hurdles, and increased investment in R&D all require a concerted effort on the part of all relevant parties. Infection prevention and control methods, proper use of antibiotics through antimicrobial stewardship programs, and educational and awareness initiatives are all necessary to halt the spread of antibiotic-resistant bacteria. While these approaches have shown promise in combating AMR, there are still hurdles that must be overcome before they can be fully implemented and maintained. In conclusion, combating AMR calls for an international coalition of healthcare professionals, government officials, and others to work together. The stakes are too high not to act, as ignoring this issue will have serious effects on people's health and the global economy.

Future developments in analyzing infection patterns, pathogen resistance, and targeted bacterial processes will revolutionize the field of bacterial infection control. One of the most important advances is the creation of diagnostic technologies that can identify bacterial strains and their resistance profiles quickly and accurately. To personalize treatments, forecast susceptibility, and lessen the spread of antibiotic resistance, precision medicine will combine patient health records with genetic and microbiome data. Massive amounts of genomic and clinical data will be analyzed by big data analytics and AI algorithms to find trends, forecast epidemics, and locate novel therapeutic targets. To eradicate drug-resistant infections, scientists will employ gene-editing tools like CRISPR. Natural antimicrobial agents, bacteriophages, and immunotherapies, among others, will rise to prominence as promising new treatment options. To effectively monitor and manage bacterial infections, a One Health approach combining coordination between human health professionals, veterinarians, environmental scientists, and legislators is required. The prevention and treatment of bacterial infections, the lessening of antibiotic resistance, and the improvement of global health outcomes are all areas where these developments hold significant promise.